Shield Therapeutics PLC Investor Presentation
07 Enero 2022 - 1:00AM
RNS Non-Regulatory
TIDMSTX
Shield Therapeutics PLC
07 January 2022
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Investor Presentation
H.C. Wainwright BIOCONNECT Virtual Conference
London, UK, 7 January, 2022: Shield Therapeutics plc (LSE: STX),
a commercial stage specialty pharmaceutical company with a focus on
addressing iron deficiency with its lead product
Accrufer(R)/Feraccru(R) (ferric maltol), announces that Greg
Madison, Chief Executive Officer of Shield, is scheduled to present
virtually at the H.C. Wainwright BIOCONNECT Virtual Conference on
10 January, 2022. Please see presentation details below:
Date/Time: Virtual presentation available on-demand on Monday,
10 January, 2022 at 7:00 a.m. ET
Presenter: Greg Madison, Chief Executive Officer
To access the virtual presentation, sign up for 1x1 meetings, or
for more information about the H.C. Wainwright BIOCONNECT Virtual
Conference, please refer to the conference website at
www.hcwevents.com/bioconnect/.
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Greg Madison, CEO +44 (0) 191 511 8500
Hans-Peter Rudolf, CFO
Nominated Adviser and Joint
Broker
Peel Hunt LLP
James Steel/Christopher Golden +44 (0)20 7418 8900
Joint Broker
finnCap Ltd
Geoff Nash/Alice Lane/George
Dollemore +44 (0)20 7220 0500
Financial PR & IR Advisor
Walbrook PR (UK Advisor)
Paul McManus/Lianne Applegarth/Alice +44 (0)20 7933 8780 or shield@walbrookpr.com
Woodings
Investor Contact (US Advisor)
LifeSci Advisors, LLC
John Mullaly +1 617 429 3548 or jmullaly@lifesciadvisors.com
About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company
with a focus on addressing iron deficiency with its lead product
Accrufer(R)/Feraccru(R) (ferric maltol), a novel, stable, non-salt
based oral therapy for adults with iron deficiency with or without
anaemia.
Shield's proprietary lead product, Accrufer(R)/Feraccru(R), has
been approved for use in the United States, European Union, UK,
Switzerland, and Australia. The product has patent coverage until
the mid-2030s. The Company recently launched Accrufer (R) in the
US. Feraccru(R) is being commercialised in the UK and European
Union by Norgine B.V., who also have the marketing rights in
Australia and New Zealand. Shield also has an exclusive license
agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the
development and commercialisation of Accrufer(R)/Feraccru(R) in
China, Hong Kong, Macau, and Taiwan, with Korea Pharma Co., Ltd. in
the Republic of Korea, and with KYE Pharmaceuticals Inc. in
Canada.
For more information, please visit www.shieldtherapeutics.com .
Follow Shield on Twitter @ShieldTx
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUNURRUSUARUR
(END) Dow Jones Newswires
January 07, 2022 02:00 ET (07:00 GMT)
Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024